TransMedics Group (NASDAQ:TMDX) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a sell rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts. “

A number of other analysts have also recently weighed in on TMDX. Canaccord Genuity started coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They issued a buy rating and a $37.00 price objective for the company. Cowen started coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They issued an outperform rating and a $40.00 price objective for the company. Morgan Stanley started coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They issued an equal weight rating for the company. Finally, JPMorgan Chase & Co. started coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They issued an overweight rating and a $34.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. TransMedics Group presently has an average rating of Hold and an average price target of $37.00.

Shares of TransMedics Group stock traded down $0.39 on Thursday, reaching $23.26. The stock had a trading volume of 100,622 shares, compared to its average volume of 132,912. The business has a 50-day moving average price of $26.28. TransMedics Group has a fifty-two week low of $19.76 and a fifty-two week high of $31.54.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, June 12th. The company reported ($4.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($4.05). The firm had revenue of $4.68 million for the quarter, compared to analyst estimates of $4.43 million. On average, equities research analysts anticipate that TransMedics Group will post -1.78 EPS for the current year.

In related news, Director Edwin M. Kania, Jr. bought 33,333 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $533,328.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Large investors have recently added to or reduced their stakes in the stock. Roubaix Capital LLC acquired a new position in TransMedics Group during the 2nd quarter valued at $4,962,000. Emerald Mutual Fund Advisers Trust acquired a new position in TransMedics Group during the 2nd quarter valued at $5,697,000. Emerald Advisers LLC acquired a new position in TransMedics Group during the 2nd quarter valued at $6,132,000. Finally, Janus Henderson Group PLC acquired a new position in TransMedics Group during the 2nd quarter valued at $15,059,000.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

See Also: What is quantitative easing?

Get a free copy of the Zacks research report on TransMedics Group (TMDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.